Business Context and Reporting Period
This Form 8-K was filed by Senseonics Holdings, Inc. on September 11, 2023, reporting events occurring on September 5, 2023, and September 8, 2023. The filing details the entry into a new senior secured term loan facility and the completion of a debt-for-equity exchange regarding outstanding convertible notes.
Key Financial Metrics and Agreements
Loan and Security Agreement
- Total Facility Size: Up to $50.0 million in senior secured term loans.
- Initial Funding: $25.0 million funded on September 8, 2023.
- Future Tranches: Up to $10.0 million (Tranche 2) and $15.0 million (Tranche 3) available upon satisfaction of conditions.
- Interest Rate: Greater of (Prime Rate + 1.40%) or 9.90%.
- Maturity Date: September 1, 2027.
- Repayment Terms: Monthly interest-only payments initially through September 1, 2026, extendable to maturity if conditions are met. Principal and interest payable thereafter.
- Fees: $375,000 facility fee paid at closing; 0.50% facility charge on future tranches; 6.95% end-of-term fee on funded amounts.
- Prepayment Penalties: 3.0% (Year 1), 2.0% (Year 2), 1.0% (Year 3+).
- Collateral: First-priority security interest in substantially all assets.
Debt-for-Equity Exchange
- Notes Exchanged: $30.8 million aggregate principal of 5.25% Convertible Senior Notes due 2025.
- Consideration Paid: $7.5 million cash plus 35.1 million newly issued common shares.
- Remaining Debt: Approximately $20.4 million of the 2025 Notes remain outstanding.
Warrant Issuance
- Initial Warrants: Issued to lenders for 832,362 shares at an exercise price of $0.6007 per share.
- Future Warrants: Additional warrants to be issued upon funding of Tranche 2 and 3, equal to 2.0% of the funded loan amount divided by the exercise price.
Material Changes and Covenants
The company has significantly altered its capital structure by securing new debt financing while simultaneously reducing its convertible note liability through a cash and equity exchange. The new Loan Agreement introduces specific financial covenants:
- Minimum Cash Covenant: Must maintain unrestricted cash equal to 30% of the outstanding loan amount.
- Performance Covenant: Commencing July 1, 2024, the company must generate net product revenue on a trailing six-month basis exceeding specified percentages.
- Restrictions: The agreement includes customary negative covenants restricting additional indebtedness, liens, investments, mergers, and dividends.
Outlook, Risks, and Contingencies
The filing highlights several risks and contingencies associated with the new financing:
- Default Risks: Events of default include payment defaults, covenant breaches, material adverse effects, and revocation of government approvals. Upon default, interest rates may increase by 4.0%, and lenders may accelerate all outstanding amounts.
- Dilution: The issuance of 35.1 million shares in the exchange and the warrant issuance (832,362 shares initially, with potential for more) represents significant potential dilution to existing shareholders.
- Liquidity Constraints: The requirement to hold 30% of the loan balance in unrestricted cash limits the immediate availability of the borrowed funds for operations.
- Future Funding Uncertainty: The availability of the remaining $25.0 million in loan tranches is contingent on satisfying specific terms and conditions.
Investor Verification Checklist
- Verify the exact volume-weighted average price used to calculate the 35.1 million shares issued in the exchange.
- Confirm the specific revenue thresholds required to satisfy the performance covenant starting July 1, 2024.
- Review the full text of the Loan Agreement (Exhibit 10.1) for detailed definitions of "Interest Only Extension Conditions."
- Assess the impact of the 6.95% end-of-term fee on the total cost of capital.
- Monitor the company's cash balance to ensure compliance with the 30% unrestricted cash covenant.